Chilton Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Chilton Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,500	Closed	-$32.3K	–	666
2025 Q4	$32.3K	Hold	1,500	–	–	﹤0.01%	376
2025 Q3	$22.9K	Hold	1,500	–	–	﹤0.01%	422
2025 Q2	$13.3K	Sell	1,500 -1,500	-50%	-$13.2K	﹤0.01%	442
2025 Q1	$23.5K	Hold	3,000	–	–	﹤0.01%	392
2024 Q4	$31.5K	Hold	3,000	–	–	﹤0.01%	378
2024 Q3	$39.3K	Hold	3,000	–	–	﹤0.01%	370
2024 Q2	$42.2K	Hold	3,000	–	–	﹤0.01%	374
2024 Q1	$50.7K	Buy	+3,000	New	+$44.7K	﹤0.01%	351

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Chilton Capital Management's AVDL Position: Q1 2026 in Review

Chilton Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,500 shares — an estimated $32.3K sold.

Chilton Capital Management first reported a position in AVDL in Q1 2024 and held it in 8 quarters. The position peaked at $50.7K in Q1 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Chilton Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Chilton Capital Management sold 1,500 Avadel Pharmaceuticals shares in Q1 2026, an estimated $32.3K.
Chilton Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 8 quarters.
Chilton Capital Management's Avadel Pharmaceuticals position peaked at $50.7K in Q1 2024.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Chilton Capital Management's 13F filing for Q1 2026, filed 11 May 2026.